Hassan S Badr1, Mahmoud A El-Hawy2, Mohammed A Helwa3. 1. Department of Pediatrics, Faculty of Medicine, Menoufia Universty, Shebin el Kom, 32511, Menoufia, Egypt. 2. Department of Pediatrics, Faculty of Medicine, Menoufia Universty, Shebin el Kom, 32511, Menoufia, Egypt. mahmodelhawy18@yahoo.com. 3. Department of Clinical Pathology, Faculty of Medicine, Menoufia Universty, Menoufia, Egypt.
Abstract
OBJECTIVES: To explore the expression of P-glycoprotein (P-gp) in the peripheral blood nucleated cells (PBNCs) of children with nephrotic syndrome in relation to their clinical response to glucocorticoid treatment. METHODS: Thirty-six children with nephrotic syndrome (20 cases of steroid-responsive and 16 cases of steroid-resistant) were examined. All the participants were subjected to complete history taking, thorough clinical examination, laboratory investigations (24-h urinary protein, serum albumin, complete blood count with differential white blood cell count, serum cholesterol, serum urea, serum creatinine) and functional assay of P-gp using FACS Calibur flowcytometry. P-gp assay was done in both groups during remission. RESULTS: P-gp activity was significantly higher in steroid-resistant than steroid-sensitive cases. CONCLUSIONS: P-gp can be used as a predictor of outcome, as a part of laboratory evaluation of the cases before starting steroid therapy, so as to determine whether to use alternative line of therapy or use one of the P-gp inhibitors with steroid therapy.
OBJECTIVES: To explore the expression of P-glycoprotein (P-gp) in the peripheral blood nucleated cells (PBNCs) of children with nephrotic syndrome in relation to their clinical response to glucocorticoid treatment. METHODS: Thirty-six children with nephrotic syndrome (20 cases of steroid-responsive and 16 cases of steroid-resistant) were examined. All the participants were subjected to complete history taking, thorough clinical examination, laboratory investigations (24-h urinary protein, serum albumin, complete blood count with differential white blood cell count, serum cholesterol, serum urea, serum creatinine) and functional assay of P-gp using FACS Calibur flowcytometry. P-gp assay was done in both groups during remission. RESULTS:P-gp activity was significantly higher in steroid-resistant than steroid-sensitive cases. CONCLUSIONS:P-gp can be used as a predictor of outcome, as a part of laboratory evaluation of the cases before starting steroid therapy, so as to determine whether to use alternative line of therapy or use one of the P-gp inhibitors with steroid therapy.